Australia's Anteris Technologies climbs on FDA nod for heart device study

Anteris Technologies

28/11/2022 24:00

** Shares of medical tech co Anteris Technologies Ltd
 AVR.AX  rise as much as 6.5% to A$23.250
    ** Stock will mark its best day since Oct. 6, if gains hold 
    ** Co says the U.S. Food and Drug Administration (FDA) has
approved early feasibility study for co's transcatheter heart
valve system 
    ** Stock hits its highest since Oct. 11 and on track for a
third straight session of gains 
    ** AVR up ~77.5% this year, as of last close
 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))